Immunosuppression, Renal Transplant Rejection
Conditions
Keywords
chronic allograft nephropathy, cytokines, kidney transplant, calcineurin inhibitors withdrawn
Brief summary
Currently, acute kidney injury is diagnosed by increased serum creatinine. However, creatinine is not a reliable marker for acute changes in renal function. The biology of the renal graft is influenced by chemokines from reperfusion (just after the kidney transplant) and throughout its course, when acute and chronic inflammatory changes occurs. Moreover, the evaluation of changes in urinary cytokines reflects kidney interstitial patterns, and can predict renal function, acute rejection episodes and their response to treatment. Today there are several studies comparing the relative immunosuppression of renal function, but few noticed its relationship with cytokines and chemokines. Thus, we proposed studying the inflammatory consequences of early calcineurin inhibitors (ICN) withdrawing in transplant patients by urine analysis. Kidney biopsy was done before ICN withdrawn and replaced by everolimus (3 months after transplant), and 1 year after transplant.
Detailed description
1. Research objectives OBJECTIVES Main Objectives: • Evaluate the urinary chemokines in kidney transplant patients taking prednisone, tacrolimus and mycophenolate sodium compared to those in use prednisone, mycophenolate sodium and everolimus as maintenance immunosuppression. Secondary Objectives: • Assess renal function (serum creatinine and its clearance estimated by the Cockcroft-Gault) and a composite outcome (acute rejection, graft loss, death and abandonment of the study) in patients taking prednisone, tacrolimus and mycophenolate sodium compared to those taking prednisone, mycophenolate sodium and everolimus as maintenance immunosuppression. 2. Scientific background, relevance and justification of the research In current clinical practice, acute kidney injury is typically diagnosed by measuring serum creatinine. Unfortunately, creatinine is an unreliable indicator during acute changes in kidney function. First, serum creatinine concentrations may not change until about 50% of kidney function has already been lost. Second, serum creatinine does not accurately depict kidney function until a steady state has been reached, which may require several days. Chemokines can influence at least three aspects of the biology of the renal graft: 1 - the restoration of blood flow in the graft can lead to injury type ischemia / reperfusion in which chemokines recruit leukocytes; 2 - receptor responses to infection during immune suppression involve chemokines and 3 - the inflammatory components in the acute rejection (RA) and interstitial fibrosis / tubular atrophy (IF/TA) are controlled by chemokines. Current data have showed urinary cytokines predicting renal function by months in renal transplanted patients. In the evaluation of urinary cytokines and chemokines in the presence of acute rejection, taken together the studies reported elevations of urinary levels of Protein-3 alpha (MIP-3α/CCL20), interleuxin-8 (IL-8/CXCL8), interleuxin-6 (IL-6), tumoral necrosis factor (TNF), interleukin- 10 (IP-10), interferon (IFN), monocyte chemoattractant protein-1 (MCP-1 / CCL2), Interferon gamma-induced protein 10 (IL-10), Monokine induced by gamma interferon (MIG/CXCL9), Interferon-inducible T-cell alpha chemoattractant (I-TAC/CXCL11), regulated upon activation normal T cell expressed and secreted (RANTES/CCL5). As predictors of complications and future changes in renal function, levels of Transforming growth factor beta (TGF-β) and interferon-gamma inducible protein 10 (IP-10/CXCL10) were associated with renal function 6 months and 4 years after transplantation (15-16). IP-10/CXCL10, MIG/CXCL9, G protein-coupled receptor 9 (GPR9/CXCR3), RANTES/CCL5 and the percentage of binding of interleukin-2 (IL-2) were associated with the occurrence of RA. IP-10/CXCL10 and MIG/CXCL9 were also considered useful as predictors of response to treatment of RA. Nankivell et al reported in 2003 that after 1year of renal transplant, 94% of patients present with chronic rejection grade I (BANFF score) and 76% present with calcineurin nephrotoxicity, although there is insufficient data about urinary cytokines at these situations. And adding new information, Hu et al reported in 2009 urinary major intrinsic protein-delta (MIP-δ), osteoprotegerin (OPG), IP-10/CXCL10, MIG/CXCL9 as good biomarkers for acute renal rejection and IF/TA. Nowadays there is a lot of studies comparing immunosuppression in relation to renal function but not so much in relation to chemokines and cytokines, which are more representative of allograft inflammation and fibrosis. So, we proposed studying the inflammatory consequences of early CNI withdrawn in renal transplant patients before the immunosuppression modification (3 months after transplant) and 1 year after kidney transplant.
Interventions
Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients over 18 years old and under 65 years old * Recipients of first kidney transplant * Donor younger than 65 years old * PRA (panel reactive antigen) ≤ 30% in class I or class II * No acute rejection episodes * Proteinuria \<1000 mg / day
Exclusion criteria
* multiple organ transplant recipient * Chronic liver failure * Asymptomatic bacteriuria or urinary infection at randomization time * Creatinine ≥ 2 mg / dL at randomization time (90 days after transplant) * Presence of uncontrolled hypercholesterolemia (≥ 350 mg / dL, ≥ 9.1 mmol / L) or hypertriglyceridemia (≥ 500 mg / dL, ≥ 5.6 mmol / L) at randomization time (90 days after transplant)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cytokines Evaluation | Urine and biopsy data are collected 90 days and 365 days after transplant. | Cd106(VCAM-1) , IP-10/CXCL10, MIG/CXCL9, MCP-1/CCL2, IL-1, RANTES, IL-8, IL12p70, TNF, IL-10, IL-6, IL-1, VEGF, FGF, CD54(ICAM-1) were analysed in urine 90 days after transplant (before randomization), and 365 days after transplant. Material were conserved at -80 Celsius, and analysed by ELISA at same time. Data was shown in MFI units |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of Renal Function | 90 days after transplant and 365 days after transplant | Evaluation of renal function (serum creatinine) 90 days after transplant and 365 days after transplant. |
Countries
Brazil
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Tacrolimus Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone with low immunologic risk . | 10 |
| Everolimus Kidney transplant patients taking tacrolimus, mycophenolate sodium and prednisone with low immunologic risk, and converted for use of mycophenolate sodium, everolimus, and prednisone after 90 days of kidney transplantation. | 12 |
| Total | 22 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 1 |
| Overall Study | Lack of Efficacy | 0 | 1 |
| Overall Study | Withdrawal by Subject | 5 | 1 |
Baseline characteristics
| Characteristic | Tacrolimus | Everolimus | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants | 12 Participants | 22 Participants |
| Region of Enrollment Brazil | 10 participants | 12 participants | 22 participants |
| Sex: Female, Male Female | 5 Participants | 6 Participants | 11 Participants |
| Sex: Female, Male Male | 5 Participants | 6 Participants | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 15 | 0 / 15 |
| other Total, other adverse events | 0 / 15 | 1 / 15 |
| serious Total, serious adverse events | 0 / 15 | 1 / 15 |
Outcome results
Cytokines Evaluation
Cd106(VCAM-1) , IP-10/CXCL10, MIG/CXCL9, MCP-1/CCL2, IL-1, RANTES, IL-8, IL12p70, TNF, IL-10, IL-6, IL-1, VEGF, FGF, CD54(ICAM-1) were analysed in urine 90 days after transplant (before randomization), and 365 days after transplant. Material were conserved at -80 Celsius, and analysed by ELISA at same time. Data was shown in MFI units
Time frame: Urine and biopsy data are collected 90 days and 365 days after transplant.
Population: 15 patients were enrolled in each group. However in tacrolimus group 5 patients didn't want to be submitted to other biopsy and to collect urine 365 days after transplant. And in everolimus group 3 patients had adverse events and was switched back to tacrolimus.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tacrolimus | Cytokines Evaluation | IL10 90days | 155 MFI |
| Tacrolimus | Cytokines Evaluation | IP10 90days | 380 MFI |
| Tacrolimus | Cytokines Evaluation | IL10 365 days | 179 MFI |
| Tacrolimus | Cytokines Evaluation | MIG 90days | 396 MFI |
| Tacrolimus | Cytokines Evaluation | IL6 90days | 282 MFI |
| Tacrolimus | Cytokines Evaluation | IL8 365days | 641 MFI |
| Tacrolimus | Cytokines Evaluation | IL6 365days | 281 MFI |
| Tacrolimus | Cytokines Evaluation | MIG 365days | 287 MFI |
| Tacrolimus | Cytokines Evaluation | IL1 90days | 212 MFI |
| Tacrolimus | Cytokines Evaluation | IP10 365days | 763 MFI |
| Tacrolimus | Cytokines Evaluation | IL1 365days | 228 MFI |
| Tacrolimus | Cytokines Evaluation | RANTES 90days | 148 MFI |
| Tacrolimus | Cytokines Evaluation | VEGF 90days | 82 MFI |
| Tacrolimus | Cytokines Evaluation | IL12 365days | 124 MFI |
| Tacrolimus | Cytokines Evaluation | VEGF 365days | 84 MFI |
| Tacrolimus | Cytokines Evaluation | RANTES 365days | 144 MFI |
| Tacrolimus | Cytokines Evaluation | FGF 90days | 39 MFI |
| Tacrolimus | Cytokines Evaluation | MCP1 90days | 2349 MFI |
| Tacrolimus | Cytokines Evaluation | FGF 365days | 30 MFI |
| Tacrolimus | Cytokines Evaluation | TNF 90days | 136 MFI |
| Tacrolimus | Cytokines Evaluation | CD106 90days | 43222 MFI |
| Tacrolimus | Cytokines Evaluation | IL12 90days | 116 MFI |
| Tacrolimus | Cytokines Evaluation | CD106 365days | 18324 MFI |
| Tacrolimus | Cytokines Evaluation | TNF 365days | 153 MFI |
| Tacrolimus | Cytokines Evaluation | CD54 90days | 1512 MFI |
| Tacrolimus | Cytokines Evaluation | MCP1 365days | 1306 MFI |
| Tacrolimus | Cytokines Evaluation | CD54 365days | 696 MFI |
| Tacrolimus | Cytokines Evaluation | IL8 90days | 495 MFI |
| Everolimus | Cytokines Evaluation | CD54 365days | 1664 MFI |
| Everolimus | Cytokines Evaluation | IL8 90days | 624 MFI |
| Everolimus | Cytokines Evaluation | IL8 365days | 435 MFI |
| Everolimus | Cytokines Evaluation | IL12 90days | 124 MFI |
| Everolimus | Cytokines Evaluation | IL12 365days | 124 MFI |
| Everolimus | Cytokines Evaluation | IP10 90days | 893 MFI |
| Everolimus | Cytokines Evaluation | IP10 365days | 147 MFI |
| Everolimus | Cytokines Evaluation | MCP1 90days | 4119 MFI |
| Everolimus | Cytokines Evaluation | MCP1 365days | 1375 MFI |
| Everolimus | Cytokines Evaluation | MIG 90days | 433 MFI |
| Everolimus | Cytokines Evaluation | MIG 365days | 580 MFI |
| Everolimus | Cytokines Evaluation | RANTES 90days | 145 MFI |
| Everolimus | Cytokines Evaluation | RANTES 365days | 155 MFI |
| Everolimus | Cytokines Evaluation | TNF 90days | 146 MFI |
| Everolimus | Cytokines Evaluation | TNF 365days | 157 MFI |
| Everolimus | Cytokines Evaluation | IL10 90days | 164 MFI |
| Everolimus | Cytokines Evaluation | IL10 365 days | 182 MFI |
| Everolimus | Cytokines Evaluation | IL6 90days | 349 MFI |
| Everolimus | Cytokines Evaluation | IL6 365days | 262 MFI |
| Everolimus | Cytokines Evaluation | IL1 90days | 215 MFI |
| Everolimus | Cytokines Evaluation | IL1 365days | 228 MFI |
| Everolimus | Cytokines Evaluation | VEGF 90days | 70 MFI |
| Everolimus | Cytokines Evaluation | VEGF 365days | 45 MFI |
| Everolimus | Cytokines Evaluation | FGF 90days | 43 MFI |
| Everolimus | Cytokines Evaluation | FGF 365days | 29 MFI |
| Everolimus | Cytokines Evaluation | CD106 90days | 28564 MFI |
| Everolimus | Cytokines Evaluation | CD106 365days | 19614 MFI |
| Everolimus | Cytokines Evaluation | CD54 90days | 1293 MFI |
Evaluation of Renal Function
Evaluation of renal function (serum creatinine) 90 days after transplant and 365 days after transplant.
Time frame: 90 days after transplant and 365 days after transplant
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Tacrolimus | Evaluation of Renal Function | Cr 365days | 1.4 mg/dL |
| Tacrolimus | Evaluation of Renal Function | Cr 90days | 1.6 mg/dL |
| Everolimus | Evaluation of Renal Function | Cr 90days | 1.3 mg/dL |
| Everolimus | Evaluation of Renal Function | Cr 365days | 1.4 mg/dL |